PacingCure
PacingCure is dedicated to developing precision gene therapies for cardiac diseases, focusing on abnormal electrical properties of the heart. Their mission is to translate scientific discoveries into innovative treatments through cutting-edge science, careful asset selection, and smart execution. They aim to revolutionize cardiac care by targeting disease mechanisms directly and delivering therapies precisely into the disease core, with platforms in clinical development to address high unmet medical needs.
Industries
Nr. of Employees
small (1-50)
PacingCure
Products
AAV-mediated gene therapy project for cardiac pacing dysfunction (TRACTION)
A development program to reprogram cardiomyocytes into pacemaker cells via AAV-mediated delivery of transcriptional regulators, intended to restore physiological heart rate in patients with pacing dysfunction.
AAV-mediated gene therapy project for cardiac pacing dysfunction (TRACTION)
A development program to reprogram cardiomyocytes into pacemaker cells via AAV-mediated delivery of transcriptional regulators, intended to restore physiological heart rate in patients with pacing dysfunction.
Services
End-to-end translational research bridging laboratory discoveries to clinical-ready therapeutic candidates, including model development, efficacy testing, and asset selection.
Optimization and validation of viral vector delivery, transcription factor overexpression strategies, and cell-specific expression control to maximize therapeutic effect and minimize off-target activity.
Identification of clinical indications, definition of endpoints and readouts, and strategic planning to enable clinical entry with regulatory and business considerations.
End-to-end translational research bridging laboratory discoveries to clinical-ready therapeutic candidates, including model development, efficacy testing, and asset selection.
Optimization and validation of viral vector delivery, transcription factor overexpression strategies, and cell-specific expression control to maximize therapeutic effect and minimize off-target activity.
Identification of clinical indications, definition of endpoints and readouts, and strategic planning to enable clinical entry with regulatory and business considerations.
Expertise Areas
- Cardiac gene therapy development
- Translational preclinical research
- Viral vector (AAV) delivery optimization
- Preclinical model development for arrhythmias
Key Technologies
- Adeno-associated virus (AAV) gene delivery
- Transcription factor–based gene expression control
- Cell type-specific regulatory elements
- Engineered heart tissues
News & Updates
European Innovation Council Support
Supported by the European Innovation Council to develop gene therapy for cardiac pacing dysfunctions.
Traction Project
A project aimed at curing life-threatening cardiac pacing dysfunctions through reprogramming cardiomyocytes.
Founded in 2016 in Amsterdam
Established as a spin-off from the Amsterdam University Medical Center, focusing on cardiac gene therapy.
Supported by European Grants
Received multiple grants including from the Dutch Heart Foundation, ZonMW, and the European Research Council.
European Innovation Council Support
Supported by the European Innovation Council to develop gene therapy for cardiac pacing dysfunctions.
Traction Project
A project aimed at curing life-threatening cardiac pacing dysfunctions through reprogramming cardiomyocytes.
Founded in 2016 in Amsterdam
Established as a spin-off from the Amsterdam University Medical Center, focusing on cardiac gene therapy.
Supported by European Grants
Received multiple grants including from the Dutch Heart Foundation, ZonMW, and the European Research Council.